Development of the system for prediction of drug-drug interactions in hepatobiliary transport process
肝胆转运过程中药物相互作用预测系统的开发
基本信息
- 批准号:13557219
- 负责人:
- 金额:$ 8.45万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2001
- 资助国家:日本
- 起止时间:2001 至 2002
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1. We succeeded in the construction of human and rat double transfectants which express human organic anion transporting polypeptide(OATP) 2 and multidrug resistance asssociated protein 2 (MRP2), and rat Oatp4 and Mrp2, respectively. We confirmed that OATP2(Oatp4) and MRP2 expressed on the basal and apical side, which is consistent with the physiological polarized expression pattern in liver. In this system, OATP2(Oatp4)/MRP2 bisubstrates such as estradiol-17β-glucuronide and pravastatin can be transported from the basal to apical compartment efficiently, compared with other direction. Moreover, rat in vivo hepatic clearance was well correlated with transcellular clearance of rat double transfectant by multiplying a scaling factor, which suggested that this system may be able to utilize the prediction of in vivo hepatic clearance.2. To evaluate the side effects and drug-drug interactions in the clinical situations, which we hypothesized the involvement of transporters, we analyzed the … More mechanism of drug-drug interaction between cyclosporin A(CyA) and cerivastatin(CER) using OATP2 expression system and human cryopreserved hepatocytes. In result, CyA potently inhibited the OATP2-mediated CER uptake and its inhibition constant was almost comparable with that of human hepatocytes and clinical unbound concentration of CyA. On the other hand, CyA slightly inhibited CER metabolism by CYP enzymes. So we suggested that one of the interaction mechanism is inhibition of hepatic uptake process mediated by OATP2. To investigate the mechanism for the expression of severe side effects (lactic acidosis) of biguanides(antidiabetes drugs), we performed the transport assay using human organic cation transporter(OCT)1 and 2 expression system to check their transport mechanism in liver and kidney. Biguanides can be transported by OCT1 and OCT2, which suggested that OCT1 is involved in hepatic uptake, whereas OCT2 in renal uptake and that OCT1-mediated hepatic uptake may be one of the trigger for lactic acidosis. Less
1.我们成功地构建了分别表达人有机阴离子转运多肽(OATP)2和多药耐药相关蛋白2(MRP 2)以及大鼠Oatp 4和Mrp 2的人和大鼠双转染子。我们证实了OATP 2(Oatp 4)和MRP 2在基底侧和顶侧表达,这与肝脏中的生理极化表达模式一致。在该系统中,OATP 2(Oatp 4)/MRP 2双底物如雌二醇-17 β-葡萄糖醛酸苷和普伐他汀可以有效地从基底室转运到顶室,而不是其他方向。此外,大鼠体内肝脏清除率与大鼠双转染子的跨细胞清除率通过乘以一个比例因子得到良好的相关性,这表明该系统可能能够利用体内肝脏清除率的预测.为了评估临床情况下的副作用和药物相互作用,我们假设转运蛋白参与,我们分析了 ...更多信息 利用OATP 2表达系统和人冻存肝细胞研究环孢菌素A(CyA)和西立伐他汀(CER)之间的药物相互作用机制。结果,CyA有效抑制OATP 2介导的CER摄取,其抑制常数几乎与人肝细胞和CyA的临床未结合浓度相当。另一方面,CyA轻微抑制CER代谢酶。因此,我们认为,抑制OATP 2介导的肝摄取过程是其作用机制之一。为了研究双胍类降糖药严重副作用(乳酸酸中毒)的表达机制,我们利用人有机阳离子转运蛋白(OCT)1和2表达系统进行转运试验,以检查其在肝脏和肾脏中的转运机制。OCT 1和OCT 2可转运双胍类药物,提示OCT 1参与肝脏摄取,而OCT 2参与肾脏摄取,OCT 1介导的肝脏摄取可能是乳酸酸中毒的触发因素之一。少
项目成果
期刊论文数量(78)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
M.Hasegawa et al.: "Functional Involvement of Rat Qrganic Anion-Transporter 3 (rOat3 ; Slc22a8) in the Renal Uptake of Organic Anions"J. Pharmacol. Exp. Ther.. 300(3). 746-753 (2002)
M.Hasekawa 等人:“大鼠 Qrganic 阴离子转运蛋白 3 (rOat3;Slc22a8) 在肾脏摄取有机阴离子中的功能参与”J。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H.Akita et al.: "Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficientg rat liver"Pharm. Res.. 18(8). 1119-1125 (2001)
H.Akita 等人:“Mrp2 缺陷型大鼠肝脏中牛磺胆酸盐的正弦外流增强”Pharm.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
松島総一郎 ほか: "ヒトOATP2とMRP2を同時発現させたダブルトランスフェクタントの評価-肝臓におけるcerivastatinの経細胞輸送特性の定量的評価に向けて-"薬理と治療. 30suppl.. S441-S444 (2002)
Soichiro Matsushima 等人:“共表达人 OATP2 和 MRP2 的双转染子的评估 - 定量评估西立伐他汀在肝脏中的转细胞转运特性 -”药理学和治疗 30suppl.. S441-S444 (2002)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
M.Sasaki et al.: "Transcellular transport of organic anions a across double-transfected MDCK II cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2(MRP2/ABCC2)"J. Biol.
M.Sasaki 等人:“有机阴离子跨细胞转运穿过双转染的 MDCK II 细胞单层,表达人有机阴离子转运多肽 (OATP2/SLC21A6) 和多药耐药相关蛋白 2(MRP2/ABCC2)”J.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
H. Kusuhara et al.: "Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2)"Drug Discovery Today. 6(4). 206-212 (2001)
H. Kusuhara 等人:“血脑屏障和血脑脊液屏障处的药物外排转运系统(第 2 部分)”今日药物发现。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUGIYAMA Yuichi其他文献
SUGIYAMA Yuichi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUGIYAMA Yuichi', 18)}}的其他基金
Development of probe drugs for the evaluation of the functions of drug transporters in vivo in humans
开发用于评估人体内药物转运蛋白功能的探针药物
- 批准号:
20249008 - 财政年份:2008
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Development of the quantitative prediction method of pharmacokinetics with considering the function of metabolic enzymes and transporters
考虑代谢酶和转运蛋白功能的药代动力学定量预测方法的开发
- 批准号:
17209005 - 财政年份:2005
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
New strategy for the drug development of CNS acting drugs by regulating drug transport across the blood-brain barrier
通过调节药物跨血脑屏障转运开发中枢神经系统药物的新策略
- 批准号:
15390035 - 财政年份:2003
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Drug design based on the substrate specificity of the efflux transporters expressed in the blood-brain barrier
基于血脑屏障中表达的外排转运蛋白的底物特异性的药物设计
- 批准号:
13470495 - 财政年份:2001
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis of the vectorial transport of amino acid and drugs in epithelial cells.
上皮细胞中氨基酸和药物的载体运输分析。
- 批准号:
12144201 - 财政年份:2000
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research on Priority Areas
Analysis of the factors governing the elimination route of therapeutic agents
控制治疗药物消除途径的因素分析
- 批准号:
11470509 - 财政年份:1999
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Role of hepatic transporters in the detoxification
肝脏转运蛋白在解毒中的作用
- 批准号:
10044243 - 财政年份:1998
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Development of recombinant proteins with an aim to increase their therapeutic activity by the regulation of intracellular sorting
开发重组蛋白,旨在通过调节细胞内分选来提高其治疗活性
- 批准号:
10557230 - 财政年份:1998
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Role of hepatic transporters in the detoxification
肝脏转运蛋白在解毒中的作用
- 批准号:
09044267 - 财政年份:1997
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for international Scientific Research
Analysis of multiplicity and polymorphism of drug transporters expressed in the liver.
肝脏中表达的药物转运蛋白的多样性和多态性分析。
- 批准号:
09470501 - 财政年份:1997
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似海外基金
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
免疫检查点抑制剂免疫介导的药物相互作用潜力的研究
- 批准号:
10677895 - 财政年份:2022
- 资助金额:
$ 8.45万 - 项目类别:
Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
- 批准号:
10406564 - 财政年份:2022
- 资助金额:
$ 8.45万 - 项目类别:
Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
免疫检查点抑制剂免疫介导的药物相互作用潜力的研究
- 批准号:
10506483 - 财政年份:2022
- 资助金额:
$ 8.45万 - 项目类别:
Genomic and drug-drug interaction mechanisms of interindividual variability in drug disposition
药物处置个体差异的基因组和药物相互作用机制
- 批准号:
10598140 - 财政年份:2022
- 资助金额:
$ 8.45万 - 项目类别:
DDI-on-a-chip: an optimized liver microphysiological system and microenvironment for complex drug-drug interaction studies
DDI-on-a-chip:用于复杂药物相互作用研究的优化肝脏微生理系统和微环境
- 批准号:
10324897 - 财政年份:2021
- 资助金额:
$ 8.45万 - 项目类别:
Mirtazapine for methamphetamine use disorder: drug-drug interaction study
米氮平治疗甲基苯丙胺使用障碍:药物相互作用研究
- 批准号:
9983371 - 财政年份:2020
- 资助金额:
$ 8.45万 - 项目类别:
Elucidation of a new mechanisms of action on drug-drug interaction of
阐明药物-药物相互作用的新作用机制
- 批准号:
19K16435 - 财政年份:2019
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
THE PURPOSE OF THE TO REQUIREMENT IS TO CONDUCT A PHASE I STUDY OF CBD-MORPHINE DRUG-DRUG INTERACTION. TRI HAS CLEARLY DEFINED THE OBJECTIVES OF THE TO IN THEIR PROPOSAL SUBMISSION.
该要求的目的是进行 CBD-吗啡药物相互作用的第一阶段研究。
- 批准号:
10044332 - 财政年份:2019
- 资助金额:
$ 8.45万 - 项目类别:
SCH: INT: Mining Drug-Drug Interaction Induced Adverse Effects from Health Record Databases
SCH:INT:从健康记录数据库中挖掘药物相互作用引起的不良反应
- 批准号:
1827472 - 财政年份:2018
- 资助金额:
$ 8.45万 - 项目类别:
Standard Grant
The evaluation of risk of increased metal absorption and elucidation of novel mechanism associated with the drug-drug interaction by chelation.
评估金属吸收增加的风险并阐明与螯合药物间相互作用相关的新机制。
- 批准号:
18K14957 - 财政年份:2018
- 资助金额:
$ 8.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists